Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 7/20 | 0.67 |
| ▸ | ATP4B | P51164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192822 | 0.80 | ATP4A (1.00) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL2191144 | 0.80 | ATP4A (1.00) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL2192969 | 0.79 | ATP4A (1.00) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL2192249 | 0.78 | ATP4A (0.97) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL10533466 | 0.76 | ATP4A (0.65) | ATP4AATP4BMEN1KMT2ACYP2D6 | |
| Phosphoric Acid SCHEMBL10920146 | 0.74 | ATP4A (0.86) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL2191328 | 0.73 | ATP4A (0.69) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL2234851 | 0.70 | L3MBTL1 (0.56) | ATP4AATP4BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2195617 | 0.70 | ATP4A (0.81) | ATP4AATP4BMEN1KMT2ACYP1A2 | |
| SCHEMBL2189454 | 0.69 | ATP4A (0.79) | ATP4AATP4BMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| EP-2521531-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-02-09 | — | — | US | disclosed |
| EP-3103437-A1 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9314415-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-8992897-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140154190-A1 | Skin Lightening Compositions | ELC MANAGEMENT, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-8722026-B2 | Skin lightening compositions | ELC MANAGEMENT, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140112877-A1 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2521531-A2 | SKIN LIGHTENING COMPOSITIONS | ELC Management LLC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110171149-A1 | Skin Lightening Compositions | ELC MANAGEMENT LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2011085015-A2 | SKIN LIGHTENING COMPOSITIONS | ELC MANAGEMENT LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-0339071-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003833-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | disclosed |
| EP-0068378-B1 | NOVEL IMIDAZO(1,2-A)PYRIDINES AND PYRAZINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| EP-0068378-A1 | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171149-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885MEN1 2283/4885 |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885MEN1 2283/4885 |
| US-20170035672-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885MEN1 2283/4885 |
| US-20140154190-A1 | Skin Lightening Compositions | TYR, MC1R, AHR | ATP4A 3964/4885ATP4B 4059/4885MEN1 2744/4885 |
| US-20140112877-A1 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885MEN1 2283/4885 |
| US-20150086497-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | ATP4A 3312/4885ATP4B 3659/4885MEN1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.